摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylic acid | 392331-87-2

中文名称
——
中文别名
——
英文名称
1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylic acid
英文别名
2'-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-carboxylic acid;1-(2-methyl-4-pyridyl)piperidine-4-carboxylic acid;1-(2-methylpyridin-4-yl)piperidine-4-carboxylic acid
1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylic acid化学式
CAS
392331-87-2
化学式
C12H16N2O2
mdl
——
分子量
220.271
InChiKey
ZPNGPLVFZZRSAO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    53.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯-6-(哌嗪-1-磺酰基)-1H-吲哚1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylic acid 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.33h, 以64%的产率得到(4-(3-chloro-1H-indole-6-sulfonyl)-piperazin-1-yl)-(2'-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
    参考文献:
    名称:
    WO2007/8146
    摘要:
    公开号:
  • 作为产物:
    描述:
    ethyl 1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylatesodium hydroxide 作用下, 以 甲醇乙醇 为溶剂, 以83%的产率得到1-(2-methyl-pyridin-4-yl)piperidine-4-carboxylic acid
    参考文献:
    名称:
    Sulfone derivatives, process for their production and use thereof
    摘要:
    一个由以下式表示的化合物: 其中R是一个环烃基团,或类似物;W是一个键,或类似物;X是一个二价碳氢基团,或类似物;Y和Z分别独立地为—N(R6)—或类似物;环A是一个含氮杂环环,或类似物;R5和R6独立地为氢原子、一个碳氢基团,或类似物;Z′是亚胺基团,或类似物;a为0、1或2;b为0或1,或其盐。
    公开号:
    US20030187023A1
点击查看最新优质反应信息

文献信息

  • Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
    申请人:Alstermark Christer
    公开号:US20080200431A1
    公开(公告)日:2008-08-21
    The invention relates to compounds of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R 1 , R 2 , R 3 and R 4 are independently selected from carbon and nitrogen, and where is nitrogen; A 1 is a single bond or a double bond; n is 0, 1, 2 or 3; each R 5 is independently selected from hydrogen, halogen, C 1-3 alkyl, oxo, oxy, oxido and thioxo; R 6 is hydrogen or oxo; m is 0, 1, 2 or 3; A 2 is a single bond or a double bond; each R 7 is independently selected from hydrogen, hydroxy, oxo, C 1-5 alkyl, carboxy, cyano, tetrazolyl, N—C 1-5 alkyltetrazolyl, oxazolyl, C 1-5 oxazolyl, isoxazolyl, C 1-5 isoxazolyl, hydroxyC 1-5 alkyl, carboxy C 1-5 alkyl, C 1-5 alkoxyoxo C 1-5 alkyl, carbamoyl, C 1-5 alkylcarbamoyl, di(C 1-5 alkyl)carbamoyl, carbamoyl C 1-4 alkyl, C 1-5 alkylcarbamoyl C 1-4 alkyl, di(C 1-5 alkyl)carbamoyl C 1-4 alkyl, hydroxy C 1-5 alkylcarbamoyl, C 1-5 alkoxy C 1-5 alkylcarbamoyl, hydroxy C 1-5 alkylcarbamoyl C 1-4 alkyl, C 1-5 alkoxy C 1-5 alkylcarbamoyl C 1-4 alkyl, —CONR 8 (CH 2 ) x S(O) p R 9 , —CONH(CH 2 ) q NR 10 R 11 , —C 1-5 alkyl-Y 1 , —COOCHR 17 R 18 and —CONR 17 R 18 ; and R 30 is hydrogen, amino, methyl or halogen; or a pharmaceutically acceptable salt thereof, said compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the compounds, to their use, to pharmaceutical compositions comprising them, to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect, and to combinations comprising them.
    本发明涉及公式(I)的化合物,化学式应在此处插入。请参阅纸质副本,其中R1、R2、R3和R4独立地选择为碳和氮,其中氮;A1是单键或双键;n为0、1、2或3;每个R5独立地选择为氢、卤素、C1-3烷基、氧、氧化物、氧化物和硫代氧;R6是氢或氧;m为0、1、2或3;A2是单键或双键;每个R7独立地选择为氢、羟基、氧、C1-5烷基、羧基、氰基、四唑基、N- C1-5烷基四唑基、噁唑基、C1-5噁唑基、异噁唑基、C1-5异噁唑基、羟基C1-5烷基、羧基C1-5烷基、C1-5烷氧氧化C1-5烷基、氨基甲酰基、C1-5烷基甲酰基、二(C1-5烷基)甲酰基、氨基甲酰基C1-4烷基、C1-5烷基甲酰基C1-4烷基、二(C1-5烷基)甲酰基C1-4烷基、羟基C1-5烷基甲酰基、C1-5烷氧基C1-5烷基甲酰基、羟基C1-5烷基甲酰基C1-4烷基、C1-5烷氧基C1-5烷基甲酰基C1-4烷基、-CONR8(CH2)xS(O)pR9,-CONH(CH2)qNR10R11,-C1-5烷基-Y1,-COOCHR17R18和-CONR17R18;R30是氢、氨基、甲基或卤素;或其药学上可接受的盐,该化合物具有抗血栓和抗凝作用,因此在人或动物的治疗方法中有用。本发明还涉及制备该化合物的方法,它们的用途,包含它们的制药组合物,用于制造用于产生抗血栓或抗凝作用的药物的制剂的用途,以及包含它们的组合物。
  • SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1302462A1
    公开(公告)日:2003-04-16
    A compound represented by the formula: wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently -N(R6)- or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z' is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.
    一种由式表示的化合物: 其中 R 是环状烃基,或类似物;W 是键,或类似物;X 是二价烃基,或类似物;Y 和 Z 各自独立地是 -N(R6)- 或类似物;环 A 是含氮杂环,或类似物;R5 和 R6 独立地是氢原子、烃基,或类似物;Z'是咪唑酰基,或类似物;a 是 0、1 或 2;b 是 0 或 1,或其盐。
  • [EN] HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA<br/>[FR] DÉRIVÉS DE SULFONAMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DU FACTEUR XA
    申请人:ASTRAZENECA AB
    公开号:WO2007008146A1
    公开(公告)日:2007-01-18
    [EN] The invention relates to compounds of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1, R2, R3 and R4 are independently selected from carbon and nitrogen, and where at least one of R1, R2, R3 and R4 is nitrogen; A1 is a single bond or a double bond; n is 0, 1, 2 or 3; each R5 is independently selected from hydrogen, halogen, C1-3 alkyl, oxo, oxy, oxido and thioxo; R6 is hydrogen or oxo; m is 0, 1, 2 or 3; A2 is a single bond or a double bond; each R7 is independently selected from hydrogen, hydroxy, oxo, C1-5alkyl, carboxy, cyano, tetrazolyl, N-C1-5alkyltetrazolyl, oxazolyl, C1-5oxazolyl, isoxazolyl, C1-5isoxazolyl, hydroxyC1-5alkyl, carboxy C1-5alkyl, C1-5alkoxyoxo C1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di(C1-5alkyl)carbamoyl, carbamoyl C1-4alkyl, C1-5alkylcarbamoyl C1-4alkyl, di(C1-5alkyl)carbamoyl C1-4alkyl, hydroxy C1-5alkylcarbamoyl, C1-5alkoxy C1-5alkylcarbamoyl, hydroxy C1-5alkylcarbamoyl C1-4alkyl, C1-5alkoxy C1-5alkylcarbamoyl C1-4alkyl, -CONR8(CH2)xS(O)pR9, -CONH(CH2)qNR10R11, -C1-5alkyl-Y1, -COOCHR17R18 and -CON R17 R18; and R30 is hydrogen, amino, methyl or halogen; or a pharmaceutically acceptable salt thereof, said compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the compounds, to their use, to pharmaceutical compositions comprising them, to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect, and to combinations comprising them.
    [FR] L'invention concerne des composés de formule (I) [Formule chimique à insérer ici. Voir copie papier] où R1, R2, R3 et R4 sont indépendamment sélectionnés entre un carbone et un azote, au moins l'un de R1, R2, R3 et R4 étant un azote ; A1 est une simple liaison ou une double liaison ; n est 0, 1, 2 ou 3 ; chaque R5 est indépendamment sélectionné entre un hydrogène, un halogène, un alkyle en C1-3, un oxo, un oxy, un oxydo et un thioxo ; R6 est un hydrogène ou un oxo ; m est 0, 1, 2 ou 3 ; A2 est une simple liaison ou une double liaison ; chaque R7 est indépendamment sélectionné entre un hydrogène, un hydroxy, un oxo, un alkyle en C1-5, un carboxy, un cyano, un tétrazolyle, un N-(alkyl en C1-5)tétrazolyle, un oxazolyle, un oxazolyle en C1-5, un isoxazolyle, un isoxazolyle en C1-5, un hydroxy(alkyle en C1-5), un carboxy(alkyle en C1-5), un (alcoxy en C1-5)oxo(alkyle en C1-5), un carbamoyle, un (alkyl en C1-5)carbamoyle, un di(alkyl en C1-5)carbamoyle, un carbamoyl(alkyle en C1-4), un (alkyl en C1-5)carbamoyl(alkyle en C1-4), un di(alkyl en C1-5)carbamoyl(alkyle en C1-4), un hydroxy(alkyl en C1-5)carbamoyle, un (alcoxy en C1-5)(alkyl en C1-5)carbamoyle, un hydroxy(alkyl en C1-5)carbamoyl(alkyle en C1-4), un (alcoxy en C1-5)(alkyl en C1-5)carbamoyl(alkyle en C1-4), un groupe -CONR8(CH2)xS(O)pR9, -CONH(CH2)qNR10R11, -(alkyl en C1-5)-Y1, -COOCHR17R18 et -CONR17R18 ; et R30 est un hydrogène, un amino, un méthyle ou un halogène ; ou un sel acceptable du point de vue pharmaceutique de ceux-ci, lesdits composés possédant des propriétés antithrombotiques et anticoagulantes et étant par conséquent utiles dans des procédés de traitement d'êtres humains ou d'animaux. L'invention concerne également des procédés pour la préparation des composés, leur utilisation, des compositions pharmaceutiques les comprenant, leur utilisation dans la fabrication de médicaments destinés à être utilisés dans la production d'un effet antithrombotique ou anticoagulant et des combinaisons les comprenant.
  • WO2007/8146
    申请人:——
    公开号:——
    公开(公告)日:——
  • Sulfone derivatives, process for their production and use thereof
    申请人:——
    公开号:US20030187023A1
    公开(公告)日:2003-10-02
    A compound represented by the formula: 1 wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently —N(R 6 )— or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z′ is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.
    一个由以下式表示的化合物: 其中R是一个环烃基团,或类似物;W是一个键,或类似物;X是一个二价碳氢基团,或类似物;Y和Z分别独立地为—N(R6)—或类似物;环A是一个含氮杂环环,或类似物;R5和R6独立地为氢原子、一个碳氢基团,或类似物;Z′是亚胺基团,或类似物;a为0、1或2;b为0或1,或其盐。
查看更多